AR1001 Phase 3 Results: Alzheimer’s Pill Slows Decline 31% in Subgroup but Misses Overall
AriBio's once-daily AR1001 slowed Alzheimer's decline 31% in patients on no other dementia drugs in the POLARIS-AD Phase 3 trial, but missed in the full population. Data, safety and next…
